Farnesol decreases serum triglycerides in rats: Identification of mechanisms including up-regulation of PPARα and down-regulation of fatty acid synthase in hepatocytes

Lipids

Volumn 43, Issue 7, 2008, Pages 619-627

  Duncan, Robin E ^a,b   Archer, Michael C ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

9 cis retinoic acid; Carnitine palmitoyl transferase 1a; Farnesol; Fatty acid synthase; Fatty acyl CoA oxidase; Peroxisome proliferator activated receptor alpha; Rat hepatocytes; Retinoid X receptor; Sterol regulatory element binding protein 1c; Triglycerides

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; ALITRETINOIN; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE 1A; FARNESOL; FATTY ACID SYNTHASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FATTY ACID OXIDATION; GENE EXPRESSION REGULATION; LIPOGENESIS; LIVER CELL; LIVER CELL CULTURE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

ACYL-COA OXIDASE; ANIMALS; CARNITINE O-PALMITOYLTRANSFERASE; CELLS, CULTURED; DOWN-REGULATION; FARNESOL; FATTY ACID SYNTHETASE COMPLEX; HEPATOCYTES; MALE; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; RETINOID X RECEPTOR BETA; RNA, MESSENGER; TRETINOIN; TRIGLYCERIDES; UP-REGULATION;

RATTUS;

EID: 47149085792     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-008-3192-3     Document Type: Article

References (36)

1. Jacobson TA, Miller M, Schaefer EJ (2007) Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther 29:763-777
2. Lewis GF (1997) Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 8:146-153
3. Marques-Lopes I, Ansorena D, Astiasaran I, Forga L, Martinez JA (2001) Postprandial de novo lipogenesis and metabolic changes induced by a high-carbohydrate, low-fat meal in lean and overweight men. Am J Clin Nutr 73:253-261
4. Diraison F, Dusserre E, Vidal H, Sothier M, Beylot M (2002) Increased hepatic lipogenesis but decreased expression of lipogenic gene in adipose tissue in human obesity. Am J Physiol Endocrinol Metab 282:E46-E51
5. Elam MB, Wilcox HG, Cagen LM, Deng X, Raghow R, Kumar P, Heimberg M, Russell JC (2001) Increased hepatic VLDL secretion, lipogenesis, and SREBP-1 expression in the corpulent JCR:LA-cp rat. J Lipid Res 42:2039-2048
6. Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzioni M, De Minicis S, Nobili L, Salzano R, Omenetti A, Pacetti D, Sigmund S, Benedetti A, Casini A (2006) A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 169:846-860
7. Meigs TE, Simoni RD (1997) Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase. Arch Biochem Biophys 345:1-9
8. He L, Mo H, Hadisusilo S, Qureshi AA, Elson CE (1997) Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr 127:668-674
9. Tatman D, Mo H (2002) Volatile isoprenoid constituents of fruits, vegetables and herbs cumulatively suppress the proliferation of murine B16 melanoma and human HL-60 leukemia cells. Cancer Lett 175:129-139
10. Horn TL, Long L, Cwik MJ, Morrissey RL, Kapetanovic IM, McCormick DL (2005) Modulation of hepatic and renal drug metabolizing enzyme activities in rats by subchronic administration of farnesol. Chemico Biol Interact 152:79-99
11. Ong TP, Heidor R, de Conti A, Dagli ML, Moreno FS (2006) Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase. Carcinogenesis 27:1194-1203
12. Meigs TE, Roseman DS, Simoni RD (1996) Regulation of 3-hydroxy-3- methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J Biol Chem 271:7916-7922
13. Voziyan PA, Goldner CM, Melnykovych G (1993) Farnesol inhibits phosphatidylcholine biosynthesis in cultured cells by decreasing cholinephosphotransferase activity. Biochem J 295(Pt 3):757-762
14. Murthy S, Tong H, Hohl RJ (2005) Regulation of fatty acid synthesis by farnesyl pyrophosphate. J Biol Chem 280:41793-41804
15. Hiyoshi H, Yanagimachi M, Ito M, Yasuda N, Okada T, Ikuta H, Shinmyo D, Tanaka K, Kurusu N, Yoshida I, Abe S, Saeki T, Tanaka H (2003) Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes. J Lipid Res 44:128-135
16. Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G (1997) Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res 57:1086-1090
17. Keller RK, Zhao Z, Chambers C, Ness GC (1996) Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver. Arch Biochem Biophys 328:324-330
18. Ide T, Tsunoda M, Mochizuki T, Murakami K (2004) Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice. Med Sci Monit 10:BR388-BR395
19. Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D (2003) Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52:1770-1778
20. Giguere V (1999) Orphan nuclear receptors: from gene to function. Endocr Rev 20:689-725
21. Pineda Torra I, Jamshidi Y, Flavell DM, Fruchart JC, Staels B (2002) Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol Endocrinol 16:1013-1028
22. Takahashi N, Kawada T, Goto T, Yamamoto T, Taimatsu A, Matsui N, Kimura K, Saito M, Hosokawa M, Miyashita K, Fushiki T (2002) Dual action of isoprenols from herbal medicines on both PPARgamma and PPARalpha in 3T3-L1 adipocytes and HepG2 hepatocytes. FEBS Lett 514:315-322
23. Hanley K, Komuves LG, Ng DC, Schoonjans K, He SS, Lau P, Bikle DD, Williams ML, Elias PM, Auwerx J, Feingold KR (2000) Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. J Biol Chem 275:11484-11491
24. Lefebvre P, Chinetti G, Fruchart JC, Staels B (2006) Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 116:571-580
25. Cagen LM, Deng X, Wilcox HG, Park EA, Raghow R, Elam MB (2005) Insulin activates the rat sterol-regulatory-element-binding protein 1c (SREBP-1c) promoter through the combinatorial actions of SREBP, LXR, Sp-1 and NF-Y cis-acting elements. Biochem J 385:207-216
26. Wang Y, Jones Voy B, Urs S, Kim S, Soltani-Bejnood M, Quigley N, Heo YR, Standridge M, Andersen B, Dhar M, Joshi R, Wortman P, Taylor JW, Chun J, Leuze M, Claycombe K, Saxton AM, Moustaid-Moussa N (2004) The human fatty acid synthase gene and de novo lipogenesis are coordinately regulated in human adipose tissue. J Nutr 134:1032-1038
27. Amin D, Rutledge RZ, Needle SN, Galczenski HF, Neuenschwander K, Scotese AC, Maguire MP, Bush RC, Hele DJ, Bilder GE, Perrone MH (1997) RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J Pharmacol Exp Ther 281:746-752
28. Hiyoshi H, Yanagimachi M, Ito M, Saeki T, Yoshida I, Okada T, Ikuta H, Shinmyo D, Tanaka K, Kurusu N, Tanaka H (2001) Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. Eur J Pharmacol 431:345-352
29. Scharnagl H, Schinker R, Gierens H, Nauck M, Wieland H, Marz W (2001) Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol 62:1545-1555
30. Ugawa T, Kakuta H, Moritani H, Matsuda K, Ishihara T, Yamaguchi M, Naganuma S, Iizumi Y, Shikama H (2000) YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol 131:63-70
31. Bradfute DL, Silva CJ, Simoni RD (1992) Squalene synthase-deficient mutant of Chinese hamster ovary cells. J Biol Chem 267:18308-18314
32. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL (1997) Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 99:846-854
33. Sato R, Yang J, Wang X, Evans MJ, Ho YK, Goldstein JL, Brown MS (1994) Assignment of the membrane attachment, DNA binding, and transcriptional activation domains of sterol regulatory element-binding protein-1 (SREBP-1). J Biol Chem 269:17267-17273
34. Roder K, Zhang L, Schweizer M (2007) SREBP-1c mediates the retinoid-dependent increase in fatty acid synthase promoter activity in HepG2. FEBS Lett 581:2715-2720
35. Schweizer M, Roder K, Zhang L, Wolf SS (2002) Transcription factors acting on the promoter of the rat fatty acid synthase gene. Biochem Soc Trans 30:1070-1072
36. Key TJ, Fraser GE, Thorogood M, Appleby PN, Beral V, Reeves G, Burr ML, Chang-Claude J, Frentzel-Beyme R, Kuzma JW, Mann J, McPherson K (1999) Mortality in vegetarians and nonvegetarians: detailed findings from a collaborative analysis of 5 prospective studies. Am J Clin Nutr 70:516S-524S